Stryker (NYSE:SYK) will release its n/a earnings data after the market closes on Tuesday, January 30th. Analysts expect Stryker to post earnings of $1.95 per share for the quarter. Stryker has set its Q4 guidance at $1.92-1.97 EPS.
Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The business had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the business earned $1.39 earnings per share. Stryker’s quarterly revenue was up 6.1% compared to the same quarter last year. On average, analysts expect Stryker to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.
Stryker (SYK) opened at $162.52 on Tuesday. Stryker has a 12-month low of $119.17 and a 12-month high of $164.20. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. The company has a market cap of $60,820.00, a price-to-earnings ratio of 34.65, a price-to-earnings-growth ratio of 2.31 and a beta of 0.78.
Several research firms have commented on SYK. SunTrust Banks reiterated a “buy” rating and set a $161.00 price objective on shares of Stryker in a research report on Monday, October 2nd. Oppenheimer set a $156.00 price objective on shares of Stryker and gave the company a “hold” rating in a research report on Monday, October 30th. Canaccord Genuity increased their price objective on shares of Stryker from $155.00 to $162.00 and gave the company a “buy” rating in a research report on Friday, October 27th. Zacks Investment Research lowered shares of Stryker from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Finally, Cowen set a $160.00 price objective on shares of Stryker and gave the company a “buy” rating in a research report on Friday, October 6th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the stock. Stryker presently has a consensus rating of “Hold” and a consensus price target of $156.60.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the sale, the insider now owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 7.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Stryker (SYK) Scheduled to Post Earnings on Tuesday” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/23/stryker-syk-scheduled-to-post-earnings-on-tuesday.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.